Replimune is a pre-revenue, cash-burning oncology biotech with 48% analyst upside and $32M of insider buying, but weak quality, 34% short interest and dependence on a single platform and a partner-supplied drug make it a binary bet.
Thesis pillars
- Platform And Supplier Concentration↓Deteriorating
- Heavy Insider Buying→Stable
- Analyst Upside To Target↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Jun 29, 2026
Replimune Group, Inc. (REPL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Below-average business quality.
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to kill tumors directly and trigger a systemic anti-tumor immune response. The company... Read more
Sell if holding. Engine safety override at $16.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.1/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Replimune Group, Inc.
About Replimune Group, Inc.
Replimune's lead product candidate, RP1, combined with Bristol Myers Squibb's nivolumab, has not yet reached the market: the FDA issued a first complete response letter in July 2025 and a second in April 2026 on the Biologics License Application for advanced melanoma, before accepting a Class 1 resubmission in June 2026 with an August 2, 2026 target action date. Replimune has generated no product revenue to date and expects an FDA advisory committee meeting in late July 2026.
Replimune operates an in-house manufacturing facility for its viral product candidates while relying on third-party collaborators for the checkpoint-blockade drugs used in combination therapy — Bristol Myers Squibb's nivolumab for RP1 and RP2 trials, Regeneron's cemiplimab under a separate collaboration, and Roche's atezolizumab and bevacizumab for a hepatocellular carcinoma signal-finding study. Beyond the melanoma-focused IGNYTE and I-3 trials for RP1, the company is advancing RP2 in metastatic uveal melanoma through the randomized Phase 2/3 REVEAL study, while RP3 development has been deprioritized. Replimune has generated no revenue from product sales and continues to fund clinical development from its cash resources, competing against other biopharmaceutical and biotechnology companies pursuing checkpoint-blockade combination approaches.
Show full overview
Replimune's regulatory setbacks illustrate concentrated pipeline risk rather than a diversified product base: the FDA's two complete response letters on the RP1 BLA both centered on the same underlying concern — that the pivotal IGNYTE trial's patient-population heterogeneity undermined its ability to serve as adequate and well-controlled evidence of effectiveness. Because RP2, RP3, and every other candidate in Replimune's pipeline are built on the same proprietary RPx platform as RP1, a platform-level manufacturing or safety problem, not just an RP1-specific trial-design dispute, could stall the entire portfolio at once rather than just the melanoma program.
See also: Healthcare · Biotechnology
From Replimune Group, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Replimune Group, Inc.
Latest news
- NEWS Replimune Reports Fiscal Second Quarter 2027 Financial Results — fiscal.ai Oct 28, 2026 neutral
- NEWS Replimune Group Q2 2027 Earnings Call Transcript — benzinga Oct 28, 2026 neutral
- NEWS Replimune Group Q2 EPS $(0.54) Beats $(0.77) Estimate — benzinga Oct 28, 2026 positive
- NEWS Replimune to Report Fiscal Second Quarter 2027 Financial Results on October 28, 2026 — fiscal.ai Oct 22, 2026 neutral
- NEWS Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma — benzinga Oct 1, 2026 positive
Generated 2026-10-29T11:48:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineRPx platform10-K Item 1A: 'all of the product candidates in our current pipeline are based on our proprietary RPx platform ... we may be required to discontinue development of all product candidates'
- HIGHSupplierBMS nivolumab supply10-K Item 1A: 'We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 34%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $14.94. Score 5.1/10, moderate confidence.
Analyst target: $16.96 (+5.6% upside). Prior stop was $14.94. Stop-loss: $14.94.
Concentration risk — Pipeline: RPx platform; Concentration risk — Supplier: BMS nivolumab supply; Quality below floor (1.5 < 4.0).
Replimune Group, Inc. trades at a P/E of N/A (forward -8.8). TrendMatrix value score: 6.0/10. Verdict: Sell.
15 analysts cover REPL with a consensus score of 4.2/5. Average price target: $20.
What does Replimune Group, Inc. do?Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx...
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to kill tumors directly and trigger a systemic anti-tumor immune response. The company has not generated any product revenue and depends on its lead candidate, RP1, combined with Bristol Myers Squibb's nivolumab, which received two FDA complete response letters (July 2025 and April 2026) before the FDA accepted a Class 1 BLA resubmission with an August 2, 2026 target action date.